Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza
Por:
Rondy M, Launay O, Castilla J, Costanzo S, Puig-Barberà J, Gefenaite G, Larrauri A, Rizzo C, Pitigoi D, Syrjänen RK, Machado A, Kurecic Filipovic S, Krisztina Horváth J, Paradowska-Stankiewicz I, Marbus S, InNHOVE/I-MOVE+working group and Moren A
Publicada:
3 ago 2017
Ahead of Print:
11 jul 2017
Resumen:
In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged >= 65 years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination.
We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection <= 7 days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons.
We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively.
Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed. (C) 2017 The Author(s). Published by Elsevier Ltd.
Filiaciones:
Rondy M:
EpiConcept, Paris, France.
Launay O:
Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France
CIC De Vaccinologie, Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Castilla J:
Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
CIBER Epidemiología y Salud Pública, Madrid, Spain
Costanzo S:
Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia), Italy
:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain
Centro de Salud Pública de Castellón, Castellón, Spain
Gefenaite G:
Department of Infectious Diseases of Lithuanian University of Health Sciences, Kaunas, Lithuania
Larrauri A:
National Centre of Epidemiology, CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Spain
Rizzo C:
Epidemiology Unit Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy
Pitigoi D:
INC Cantacuzino, Bucharest, Romania
Syrjänen RK:
Impact Assessment Unit, National Institute for Health and Welfare (THL), Tampere, Finland
Machado A:
Epidemiology Research Unit, Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
Kurecic Filipovic S:
Epidemiology Service, Croatian Institute of Public Health, Zagreb, Croatia
Krisztina Horváth J:
National Centre for Epidemiology, Department of Communicable Disease Prevention and Surveillance, Budapest, Hungary
Paradowska-Stankiewicz I:
Department of Epidemiology, National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland
Marbus S:
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Moren A:
EpiConcept, Paris, France
Open Access
|